skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Appendix B: Drug Characteristics Tables

Characteristics of Fusion Inhibitor

(Last updated:1/29/2008; last reviewed:2/12/2013)

Click here to view this table as an image

Appendix B, Table 5. Characteristics of Fusion Inhibitor
Generic Name (Abbreviation)/ Trade Name Formulations   Dosing Recommendation Serum Half-Life  Elimination  Storage  Adverse Events
(Also see Table 13.)
Enfuvirtide
(T20)/
Fuzeon
  • Injectable; supplied as lyophilized powder
  • Each vial contains 108 mg of T20; reconstitute with 1.1mL of sterile water for injection for delivery of approximately 90 mg/1 mL.
90 mg (1mL) subcutaneously BID 3.8 hours Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool Store at room temperature (up to 25ºC or 77ºF). Re-constituted solution should be refrigerated at 2ºC–8ºC (36ºF–46ºF) and used within 24 hours.
  • Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients
  • Increased incidence of bacterial pneumonia
  • HSR (<1% of patients): Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.

Key to Abbreviations: BID = twice daily, HSR = hypersensitivity reaction, T20 = enfuvirtide